Sienna Biopharmaceuticals Inc (NASDAQ:SNNA) Expected to Post Earnings of -$0.43 Per Share

Wall Street analysts expect Sienna Biopharmaceuticals Inc (NASDAQ:SNNA) to announce earnings per share (EPS) of ($0.43) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Sienna Biopharmaceuticals’ earnings. Sienna Biopharmaceuticals reported earnings per share of ($1.00) during the same quarter last year, which suggests a positive year-over-year growth rate of 57%. The business is expected to issue its next quarterly earnings results on Thursday, August 8th.

Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that follow Sienna Biopharmaceuticals.

Sienna Biopharmaceuticals (NASDAQ:SNNA) last announced its earnings results on Wednesday, May 8th. The company reported ($0.67) earnings per share for the quarter.

A number of equities analysts recently weighed in on the stock. JPMorgan Chase & Co. upped their target price on shares of Vermilion Energy from C$42.00 to C$43.00 in a research note on Monday, May 13th. Zacks Investment Research lowered shares of Garrett Motion from a “hold” rating to a “sell” rating in a research note on Wednesday, March 20th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $21.67.

Institutional investors have recently bought and sold shares of the company. Paloma Partners Management Co acquired a new position in shares of Sienna Biopharmaceuticals during the 4th quarter worth about $28,000. Dimensional Fund Advisors LP acquired a new position in shares of Sienna Biopharmaceuticals during the 4th quarter worth about $36,000. Rhumbline Advisers boosted its stake in shares of Sienna Biopharmaceuticals by 52.9% during the 4th quarter. Rhumbline Advisers now owns 19,377 shares of the company’s stock worth $45,000 after buying an additional 6,702 shares during the last quarter. LLBH Private Wealth Management LLC acquired a new position in shares of Sienna Biopharmaceuticals during the 1st quarter worth about $49,000. Finally, Raymond James & Associates acquired a new position in shares of Sienna Biopharmaceuticals during the 4th quarter worth about $54,000. Institutional investors own 51.32% of the company’s stock.

NASDAQ SNNA remained flat at $$0.79 on Friday. 67,611 shares of the company were exchanged, compared to its average volume of 218,365. The company has a debt-to-equity ratio of 0.90, a quick ratio of 2.61 and a current ratio of 2.61. Sienna Biopharmaceuticals has a 12-month low of $0.72 and a 12-month high of $18.05. The stock’s fifty day moving average price is $1.06.

Sienna Biopharmaceuticals Company Profile

Sienna Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of psoriasis and associated pruritus; and SNA-125, a topical dual Janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus.

Featured Article: What is a capital gains distribution?

Get a free copy of the Zacks research report on Sienna Biopharmaceuticals (SNNA)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Sienna Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharmaceuticals and related companies with's FREE daily email newsletter.